{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:43:29Z","timestamp":1790790209618,"version":"4.1.0"},"reference-count":163,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cardiac involvement has a profound effect on the prognosis of patients with systemic amyloidosis. Therapeutic methods for suppressing the production of causative proteins have been developed for ATTR amyloidosis and AL amyloidosis, which show cardiac involvement, and the prognosis has been improved. However, a method for removing deposited amyloid has not been established. Methods for reducing cytotoxicity caused by amyloid deposition and amyloid precursor protein to protect cardiovascular cells are also needed. In this review, we outline the molecular mechanisms and treatments of cardiac amyloidosis.<\/jats:p>","DOI":"10.3390\/ijms23010025","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T09:50:43Z","timestamp":1640080243000},"page":"25","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Molecular Mechanisms of Cardiac Amyloidosis"],"prefix":"10.3390","volume":"23","author":[{"given":"Yukihiro","family":"Saito","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Hospital, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8845-3626","authenticated-orcid":false,"given":"Kazufumi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System","volume":"68","author":"Grogan","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/j.jcmg.2019.06.023","article-title":"Myocardial Amyloidosis: The Exemplar Interstitial Disease","volume":"12","author":"Fontana","year":"2019","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V79.7.1817.1817","article-title":"Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989","volume":"79","author":"Kyle","year":"1992","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2011-07-370031","article-title":"High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement","volume":"119","author":"Madan","year":"2012","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"14228","DOI":"10.1021\/acs.jmedchem.0c00934","article-title":"Transthyretin Amyloidogenesis Inhibitors: From Discovery to Current Developments","volume":"63","author":"Yokoyama","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/13506129.2020.1835263","article-title":"Amyloid nomenclature 2020: Update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"27","author":"Benson","year":"2020","journal-title":"Amyloid"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.mayocp.2020.06.029","article-title":"Amyloid Typing by Mass Spectrometry in Clinical Practice: A Comprehensive Review of 16,175 Samples","volume":"95","author":"Dasari","year":"2020","journal-title":"Mayo Clin. Proc."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Rognoni, P., Mazzini, G., Caminito, S., Palladini, G., and Lavatelli, F. (2021). Dissecting the Molecular Features of Systemic Light Chain (AL) Amyloidosis: Contributions from Proteomics. Medicina, 57.","DOI":"10.3390\/medicina57090916"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/his.12793","article-title":"Correlation of histomorphological pattern of cardiac amyloid deposition with amyloid type: A histological and proteomic analysis of 108 cases","volume":"68","author":"Larsen","year":"2016","journal-title":"Histopathology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0002-9343(00)00471-X","article-title":"Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis","volume":"109","author":"Mueller","year":"2000","journal-title":"Am. J. Med."},{"key":"ref_16","first-page":"1287","article-title":"Obstructive intramural coronary amyloidosis and myocardial ischemia are common in primary amyloidosis","volume":"118","author":"Wittich","year":"2005","journal-title":"Am. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.carpath.2006.09.011","article-title":"Deposition of amyloid proteins in the epicardial coronary arteries of 58 patients with primary systemic amyloidosis","volume":"16","author":"Wittich","year":"2007","journal-title":"Cardiovasc. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jaccao.2019.08.002","article-title":"ALAmyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and Management","volume":"1","author":"Witteles","year":"2019","journal-title":"JACC Cardio Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Koike, H., and Katsuno, M. (2021). The Ultrastructure of Tissue Damage by Amyloid Fibrils. Molecules, 26.","DOI":"10.3390\/molecules26154611"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1016\/j.febslet.2012.07.029","article-title":"Clearance of extracellular misfolded proteins in systemic amyloidosis: Experience with transthyretin","volume":"586","author":"Almeida","year":"2012","journal-title":"FEBS Lett."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1073\/pnas.87.7.2843","article-title":"Fibril in senile systemic amyloidosis is derived from normal transthyretin","volume":"87","author":"Westermark","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1515\/CCLM.2002.223","article-title":"Transthyretin as a thyroid hormone carrier: Function revisited","volume":"40","author":"Palha","year":"2002","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jsb.2011.12.022","article-title":"Hydrogen-bond network and pH sensitivity in transthyretin: Neutron crystal structure of human transthyretin","volume":"177","author":"Yokoyama","year":"2012","journal-title":"J. Struct. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0022-2836(78)90368-6","article-title":"Structure of prealbumin: Secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A","volume":"121","author":"Blake","year":"1978","journal-title":"J. Mol. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"15525","DOI":"10.1021\/bi051608t","article-title":"The pathway by which the tetrameric protein transthyretin dissociates","volume":"44","author":"Foss","year":"2005","journal-title":"Biochemistry"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"12119","DOI":"10.1021\/bi00096a024","article-title":"Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity","volume":"32","author":"McCutchen","year":"1993","journal-title":"Biochemistry"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"32943","DOI":"10.1074\/jbc.274.46.32943","article-title":"The tetrameric protein transthyretin dissociates to a non-native monomer in solution. A novel model for amyloidogenesis","volume":"274","author":"Quintas","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.str.2004.08.005","article-title":"Anatomy of an amyloidogenic intermediate: Conversion of beta-sheet to alpha-sheet structure in transthyretin at acidic pH","volume":"12","author":"Armen","year":"2004","journal-title":"Structure"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"766830","DOI":"10.3389\/fmolb.2021.766830","article-title":"Aggregation-Prone Structural Ensembles of Transthyretin Collected With Regression Analysis for NMR Chemical Shift","volume":"8","author":"Yang","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1021\/bi301313b","article-title":"Age-related oxidative modifications of transthyretin modulate its amyloidogenicity","volume":"52","author":"Zhao","year":"2013","journal-title":"Biochemistry"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1096\/fj.11-189571","article-title":"Why are some amyloidoses systemic? Does hepatic \u201cchaperoning at a distance\u201d prevent cardiac deposition in a transgenic model of human senile systemic (transthyretin) amyloidosis?","volume":"26","author":"Buxbaum","year":"2012","journal-title":"FASEB J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1080\/10715760600918142","article-title":"Protein oxidation and aging","volume":"40","author":"Stadtman","year":"2006","journal-title":"Free Radic Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"101194","DOI":"10.1016\/j.arr.2020.101194","article-title":"Healthful aging mediated by inhibition of oxidative stress","volume":"64","author":"Vatner","year":"2020","journal-title":"Ageing Res. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"6470","DOI":"10.1021\/bi952501g","article-title":"The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid","volume":"35","author":"Lai","year":"1996","journal-title":"Biochemistry"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jmb.2008.07.029","article-title":"Structural insight into pH-induced conformational changes within the native human transthyretin tetramer","volume":"382","author":"Palaninathan","year":"2008","journal-title":"J. Mol. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Si, J.B., Kim, B., and Kim, J.H. (2021). Transthyretin Misfolding, A Fatal Structural Pathogenesis Mechanism. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094429"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00109-010-0695-1","article-title":"Variation in amount of wild-type transthyretin in different fibril and tissue types in ATTR amyloidosis","volume":"89","author":"Ihse","year":"2011","journal-title":"J. Mol. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/path.1759","article-title":"Amyloid deposits in transthyretin-derived amyloidosis: Cleaved transthyretin is associated with distinct amyloid morphology","volume":"206","author":"Gustavsson","year":"2005","journal-title":"J. Pathol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","article-title":"Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospective, Observational Cohort Study","volume":"133","author":"Connors","year":"2016","journal-title":"Circulation"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","article-title":"Clinical characteristics of wild-type transthyretin cardiac amyloidosis: Disproving myths","volume":"38","author":"Gagliardi","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1073\/pnas.75.9.4499","article-title":"Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy","volume":"75","author":"Costa","year":"1978","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"E2403","DOI":"10.1002\/humu.22619","article-title":"Online registry for mutations in hereditary amyloidosis including nomenclature recommendations","volume":"35","author":"Rowczenio","year":"2014","journal-title":"Hum. Mutat."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0014-5793(97)01398-7","article-title":"The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution","volume":"418","author":"Quintas","year":"1997","journal-title":"FEBS Lett."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1021\/bi027319b","article-title":"D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: A prescription for central nervous system amyloidosis?","volume":"42","author":"Sekijima","year":"2003","journal-title":"Biochemistry"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0022-2836(02)00425-4","article-title":"Decreased thermodynamic stability as a crucial factor for familial amyloidotic polyneuropathy","volume":"320","author":"Niraula","year":"2002","journal-title":"J. Mol. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"15053","DOI":"10.1021\/bi0353528","article-title":"Biophysical analyses of the transthyretin variants, Tyr114His and Tyr116Ser, associated with familial amyloidotic polyneuropathy","volume":"42","author":"Shinohara","year":"2003","journal-title":"Biochemistry"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"14943","DOI":"10.1073\/pnas.261419998","article-title":"The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis","volume":"98","author":"Jiang","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41598-018-37230-1","article-title":"Transthyretin Aggregation Pathway toward the Formation of Distinct Cytotoxic Oligomers","volume":"9","author":"Dasari","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Frangolho, A., Correia, B.E., Vaz, D.C., Almeida, Z.L., and Brito, R.M.M. (2020). Oligomerization Profile of Human Transthyretin Variants with Distinct Amyloidogenicity. Molecules, 25.","DOI":"10.3390\/molecules25235698"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cell.2005.01.018","article-title":"The biological and chemical basis for tissue-selective amyloid disease","volume":"121","author":"Sekijima","year":"2005","journal-title":"Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","article-title":"Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: An Italian perspective","volume":"34","author":"Rapezzi","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1056\/NEJM199702133360703","article-title":"Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans","volume":"336","author":"Jacobson","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1073\/pnas.1317488111","article-title":"Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis","volume":"111","author":"Mangione","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/j.1460-2075.1993.tb05708.x","article-title":"Modifications of transthyretin in amyloid fibrils: Analysis of amyloid from homozygous and heterozygous individuals with the Met30 mutation","volume":"12","author":"Wahlqvist","year":"1993","journal-title":"EMBO J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.15252\/emmm.201505357","article-title":"Anovel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis","volume":"7","author":"Marcoux","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"14192","DOI":"10.1074\/jbc.RA118.003990","article-title":"Plasminogen activation triggers transthyretin amyloidogenesis in vitro","volume":"293","author":"Mangione","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Bezerra, F., Niemietz, C., Schmidt, H.H.J., Zibert, A., Guo, S., Monia, B.P., Gon\u00e7alves, P., Saraiva, M.J., and Almeida, M.R. (2021). In Vitro and In Vivo Effects of SerpinA1 on the Modulation of Transthyretin Proteolysis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22179488"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"44709","DOI":"10.1038\/srep44709","article-title":"Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation","volume":"7","author":"Almeida","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/13506120600722449","article-title":"R104H may suppress transthyretin amyloidogenesis by thermodynamic stabilization, but not by the kinetic mechanism characterizing T119 interallelic trans-suppression","volume":"13","author":"Sekijima","year":"2006","journal-title":"Amyloid"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1126\/science.1079589","article-title":"Prevention of transthyretin amyloid disease by changing protein misfolding energetics","volume":"299","author":"Wiseman","year":"2003","journal-title":"Science"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"16427","DOI":"10.1073\/pnas.202495199","article-title":"Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity","volume":"99","author":"Jiang","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41467-019-08609-z","article-title":"Amolecular mechanism for transthyretin amyloidogenesis","volume":"10","author":"Yee","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1161\/ATVBAHA.113.301273","article-title":"Genetic stabilization of transthyretin, cerebrovascular disease, and life expectancy","volume":"33","author":"Hornstrup","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1080\/13506129.2020.1758658","article-title":"Transthyretin-stabilising mutation T119M is not associated with protection against vascular disease or death in the UK Biobank","volume":"27","author":"Parker","year":"2020","journal-title":"Amyloid"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/path.2618","article-title":"Chain reaction of amyloid fibril formation with induction of basement membrane in familial amyloidotic polyneuropathy","volume":"219","author":"Misumi","year":"2009","journal-title":"J. Pathol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bbrc.2011.04.133","article-title":"Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs","volume":"410","author":"Bourgault","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e00172","DOI":"10.1042\/BSR20140155","article-title":"Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: Insights into early events of non-fibrillar tissue damage","volume":"35","author":"Manral","year":"2015","journal-title":"Biosci. Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/j.bpj.2016.09.010","article-title":"Biochemical and Electrophysiological Modification of Amyloid Transthyretin on Cardiomyocytes","volume":"111","author":"Sartiani","year":"2016","journal-title":"Biophys. J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00392-020-01801-y","article-title":"Impaired in vitro growth response of plasma-treated cardiomyocytes predicts poor outcome in patients with transthyretin amyloidosis","volume":"110","author":"Hein","year":"2021","journal-title":"Clin. Res. Cardiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1432-2277.2008.00737.x","article-title":"High incidence of thrombotic complications early after liver transplantation for familial amyloidotic polyneuropathy","volume":"22","author":"Bispo","year":"2009","journal-title":"Transpl. Int."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"31752","DOI":"10.1074\/jbc.M113.469858","article-title":"Transthyretin proteins regulate angiogenesis by conferring different molecular identities to endothelial cells","volume":"288","author":"Nunes","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0161-5890(94)90001-9","article-title":"Anatomy of the antibody molecule","volume":"31","author":"Padlan","year":"1994","journal-title":"Mol. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1107\/S0907444902004183","article-title":"Three-dimensional structure of an immunoglobulin light-chain dimer with amyloidogenic properties","volume":"58","author":"Bourne","year":"2002","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/s41467-019-09133-w","article-title":"Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient","volume":"10","author":"Swuec","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41467-019-09032-0","article-title":"Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis","volume":"10","author":"Radamaker","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/s41467-021-21126-2","article-title":"Cryo-EM reveals structural breaks in a patient-derived amyloid fibril from systemic AL amyloidosis","volume":"12","author":"Radamaker","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"6516","DOI":"10.1038\/s41467-021-26845-0","article-title":"Dissection of the amyloid formation pathway in AL amyloidosis","volume":"12","author":"Kazman","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e52200","DOI":"10.7554\/eLife.52300","article-title":"Fatal amyloid formation in a patient\u2019s antibody light chain is caused by a single point mutation","volume":"9","author":"Kazman","year":"2020","journal-title":"Elife"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/circ.104.14.1594","article-title":"Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts","volume":"104","author":"Liao","year":"2001","journal-title":"Circulation"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1096\/fj.15-272179","article-title":"Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis","volume":"29","author":"Lavatelli","year":"2015","journal-title":"FASEB J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"15661","DOI":"10.1038\/s41598-017-15424-3","article-title":"Proteotoxicity in cardiac amyloidosis: Amyloidogenic light chains affect the levels of intracellular proteins in human heart cells","volume":"7","author":"Imperlini","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s00395-013-0378-5","article-title":"Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity","volume":"108","author":"Guan","year":"2013","journal-title":"Basic Res. Cardiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/01.RES.0000126569.75419.74","article-title":"Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress","volume":"94","author":"Brenner","year":"2004","journal-title":"Circ. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1073\/pnas.0912263107","article-title":"Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway","volume":"107","author":"Shi","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"McWilliams-Koeppen, H.P., Foster, J.S., Hackenbrack, N., Ramirez-Alvarado, M., Donohoe, D., Williams, A., Macy, S., Wooliver, C., Wortham, D., and Morrell-Falvey, J. (2015). Light Chain Amyloid Fibrils Cause Metabolic Dysfunction in Human Cardiomyocytes. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0137716"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/s41375-019-0640-4","article-title":"Light chain amyloidosis induced inflammatory changes in cardiomyocytes and adipose-derived mesenchymal stromal cells","volume":"34","author":"Jordan","year":"2020","journal-title":"Leukemia"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCHEARTFAILURE.108.788687","article-title":"Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: Relationship to structural, functional myocardial changes and to light chain amyloid deposition","volume":"1","author":"Biolo","year":"2008","journal-title":"Circ. Heart Fail."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.bbadis.2008.05.005","article-title":"Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of Familial Amyloidotic Polyneuropathy","volume":"1782","author":"Macedo","year":"2008","journal-title":"Biochim. Biophys. Acta-Mol. Basis Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1096\/fj.05-4509com","article-title":"Doxycycline disrupts transthyretin amyloid: Evidence from studies in a FAP transgenic mice model","volume":"20","author":"Cardoso","year":"2006","journal-title":"Faseb J."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1479-5876-8-74","article-title":"Synergy of combined doxycycline\/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: Studies in FAP mouse models","volume":"8","author":"Cardoso","year":"2010","journal-title":"J. Transl. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/13506129.2012.678508","article-title":"Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: A phase II study","volume":"19","author":"Obici","year":"2012","journal-title":"Amyloid"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cardfail.2019.01.006","article-title":"Clinical Experience With the Use of Doxycycline and Ursodeoxycholic Acid for the Treatment of Transthyretin Cardiac Amyloidosis","volume":"25","author":"Karlstedt","year":"2019","journal-title":"J. Card. Fail."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja206279b","article-title":"Lysine-specific molecular tweezers are broad-spectrum inhibitors of assembly and toxicity of amyloid proteins","volume":"133","author":"Sinha","year":"2011","journal-title":"J. Am. Chem. Soc."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s13311-013-0256-8","article-title":"Molecular tweezers targeting transthyretin amyloidosis","volume":"11","author":"Ferreira","year":"2014","journal-title":"Neurotherapeutics"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1016\/j.febslet.2011.06.030","article-title":"Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation","volume":"585","author":"Ferreira","year":"2011","journal-title":"FEBS Lett."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bbadis.2012.10.007","article-title":"Dietary curcumin counteracts extracellular transthyretin deposition: Insights on the mechanism of amyloid inhibition","volume":"1832","author":"Ferreira","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Ferreira, N., Saraiva, M.J., and Almeida, M.R. (2012). Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: \u201cin vivo\u201d evidence from FAP mice models. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0029933"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"26623","DOI":"10.1038\/srep26623","article-title":"Curcumin: A multi-target disease-modifying agent for late-stage transthyretin amyloidosis","volume":"6","author":"Ferreira","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"15051","DOI":"10.1073\/pnas.93.26.15051","article-title":"Inhibiting transthyretin amyloid fibril formation via protein stabilization","volume":"93","author":"Miroy","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1021\/ar020073i","article-title":"Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: A focus on the transthyretin amyloidoses","volume":"38","author":"Johnson","year":"2005","journal-title":"Acc. Chem. Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0968-0896(98)00130-8","article-title":"Discovering transthyretin amyloid fibril inhibitors by limited screening","volume":"6","author":"Baures","year":"1998","journal-title":"Bioorganic Med. Chem."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0969-2126(02)00771-2","article-title":"Screening transthyretin amyloid fibril inhibitors: Characterization of novel multiprotein, multiligand complexes by mass spectrometry","volume":"10","author":"McCammon","year":"2002","journal-title":"Structure"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.bbrc.2006.07.109","article-title":"Cell based screening of inhibitors of transthyretin aggregation","volume":"348","author":"Reixach","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.bmc.2010.12.050","article-title":"Acompetition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin","volume":"19","author":"Choi","year":"2011","journal-title":"Bioorganic Med. Chem."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"97ra81","DOI":"10.1126\/scitranslmed.3002473","article-title":"Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity","volume":"3","author":"Alhamadsheh","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/labinvest.3700059","article-title":"Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants","volume":"84","author":"Miller","year":"2004","journal-title":"Lab. Invest."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.neures.2006.08.014","article-title":"Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis","volume":"56","author":"Tojo","year":"2006","journal-title":"Neurosci. Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1080\/13506120600960882","article-title":"Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis","volume":"13","author":"Sekijima","year":"2006","journal-title":"Amyloid"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/13506129.2014.997872","article-title":"Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis","volume":"22","author":"Sekijima","year":"2015","journal-title":"Amyloid"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1751-7133.2012.00303.x","article-title":"Diflunisal for ATTR cardiac amyloidosis","volume":"18","author":"Helmke","year":"2012","journal-title":"Congest. Heart Fail."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1021\/acs.jmedchem.8b00817","article-title":"Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis","volume":"61","author":"Miller","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"9992","DOI":"10.1073\/pnas.1300761110","article-title":"AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin","volume":"110","author":"Penchala","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"10787","DOI":"10.1038\/ncomms10787","article-title":"Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity","volume":"7","author":"Gallego","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/febs.15339","article-title":"Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis","volume":"288","author":"Pinheiro","year":"2021","journal-title":"FEBS J."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/13506129.2019.1597702","article-title":"Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: Proof-of-concept study","volume":"26","author":"Gamez","year":"2019","journal-title":"Amyloid"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jmb.2011.12.060","article-title":"The transthyretin amyloidoses: From delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug","volume":"421","author":"Johnson","year":"2012","journal-title":"J. Mol. Biol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/lt.21395","article-title":"Marked regression of abdominal fat amyloid in patients with familial amyloid polyneuropathy during long-term follow-up after liver transplantation","volume":"14","author":"Tsuchiya","year":"2008","journal-title":"Liver Transpl."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.mayocp.2019.10.036","article-title":"Regression of Bone-Tracer Uptake in Cardiac Transthyretin Amyloidosis","volume":"95","author":"Groothof","year":"2020","journal-title":"Mayo Clin. Proc."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"Single Administration of CRISPR\/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1073\/pnas.90.6.2375","article-title":"Disruption of the transthyretin gene results in mice with depressed levels of plasma retinol and thyroid hormone","volume":"90","author":"Episkopou","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"21431","DOI":"10.1074\/jbc.M402212200","article-title":"Transthyretin, a new cryptic protease","volume":"279","author":"Liz","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1042\/BJ20082090","article-title":"Substrate specificity of transthyretin: Identification of natural substrates in the nervous system","volume":"419","author":"Liz","year":"2009","journal-title":"Biochem. J."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/iub.340","article-title":"Aboard transthyretin: From transport to cleavage","volume":"62","author":"Liz","year":"2010","journal-title":"IUBMB Life"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/j.1471-4159.2010.07047.x","article-title":"CSFtransthyretin neuroprotection in a mouse model of brain ischemia","volume":"115","author":"Santos","year":"2010","journal-title":"J. Neurochem."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/labinvest.2013.83","article-title":"Fibroblasts endocytose and degrade transthyretin aggregates in transthyretin-related amyloidosis","volume":"93","author":"Misumi","year":"2013","journal-title":"Lab. Invest."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"25096","DOI":"10.1074\/jbc.M116.738138","article-title":"Novel Antibody for the Treatment of Transthyretin Amyloidosis","volume":"291","author":"Hosoi","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/eurheartj\/ehz695","article-title":"Anovel monoclonal antibody targeting aggregated transthyretin facilitates its removal and functional recovery in an experimental model","volume":"41","author":"George","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1038\/s41467-021-23274-x","article-title":"Ahuman antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells","volume":"12","author":"Michalon","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/13506129.2016.1148025","article-title":"Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin","volume":"23","author":"Higaki","year":"2016","journal-title":"Amyloid"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1073\/pnas.96.6.3108","article-title":"Exposure of cryptic epitopes on transthyretin only in amyloid and in amyloidogenic mutants","volume":"96","author":"Goldsteins","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/lt.24058","article-title":"Liver transplantation in transthyretin amyloidosis: Issues and challenges","volume":"21","author":"Carvalho","year":"2015","journal-title":"Liver Transpl."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1097\/TP.0b013e31824b3749","article-title":"Amyloid fibril composition as a predictor of development of cardiomyopathy after liver transplantation for hereditary transthyretin amyloidosis","volume":"93","author":"Gustafsson","year":"2012","journal-title":"Transplantation"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00007890-199807270-00016","article-title":"Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: Implications for amyloid fibrillogenesis","volume":"66","author":"Stangou","year":"1998","journal-title":"Transplantation"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1006\/bbrc.2000.3203","article-title":"Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin","volume":"274","author":"Yazaki","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"E6741","DOI":"10.1073\/pnas.1805131115","article-title":"Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition","volume":"115","author":"Saelices","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"6130","DOI":"10.1074\/jbc.RA118.005257","article-title":"Apair of peptides inhibits seeding of the hormone transporter transthyretin into amyloid fibrils","volume":"294","author":"Saelices","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa070484","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"357","author":"Jaccard","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1182\/blood-2011-01-330738","article-title":"Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: Long-term results in a series of 421 patients","volume":"118","author":"Cibeira","year":"2011","journal-title":"Blood"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/bjh.13155","article-title":"Guidelines on the management of AL amyloidosis","volume":"168","author":"Wechalekar","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaccao.2021.09.003","article-title":"ALAmyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies: JACC: CardioOncology State-of-the-Art Review","volume":"3","author":"Bianchi","year":"2021","journal-title":"JACC Cardio Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.3389\/fimmu.2018.01676","article-title":"CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance","volume":"9","author":"Seckinger","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-016-0283-0","article-title":"Daratumumab: A first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma","volume":"9","author":"Sanchez","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1309\/74R4TB90BUWH27JX","article-title":"Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma","volume":"121","author":"Lin","year":"2004","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3324\/haematol.2008.004119","article-title":"Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chain","volume":"94","author":"Bijzet","year":"2009","journal-title":"Haematologica"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1161\/CIRCULATIONAHA.114.009135","article-title":"Regression of cardiac amyloidosis after stem cell transplantation assessed by cardiovascular magnetic resonance imaging","volume":"129","author":"Brahmanandam","year":"2014","journal-title":"Circulation"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.2169\/internalmedicine.53.2065","article-title":"Marked and rapid regression of hepatic amyloid deposition in a patient with systemic light chain (AL) amyloidosis after high-dose melphalan therapy with stem cell transplantation","volume":"53","author":"Katoh","year":"2014","journal-title":"Intern. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jcmg.2017.02.012","article-title":"CMR-Verified Regression of Cardiac AL Amyloid After Chemotherapy","volume":"11","author":"Treibel","year":"2018","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1182\/blood-2011-04-351643","article-title":"Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis","volume":"118","author":"Ward","year":"2011","journal-title":"Blood"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood.V120.21.3138.3138","article-title":"Doxycycline Used As Post Transplant Antibacterial Prophylaxis Improves Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Stem Cell Transplantation","volume":"120","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1182\/blood.V124.21.3485.3485","article-title":"AMatched Case Control Study of Doxycycline Added to Chemotherapy for Reducing Early Mortality in Patients with Advanced Cardiac AL Amyloidosis from the Alchemy Study Cohort","volume":"124","author":"Wechalekar","year":"2014","journal-title":"Blood"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"100361","DOI":"10.1016\/j.eclinm.2020.100361","article-title":"Adjuvant doxycycline to enhance anti-amyloid effects: Results from the dual phase 2 trial","volume":"23","author":"Szabo","year":"2020","journal-title":"EClinicalMedicine"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature09494","article-title":"Antibodies to human serum amyloid P component eliminate visceral amyloid deposits","volume":"468","author":"Bodin","year":"2010","journal-title":"Nature"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","article-title":"Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component","volume":"373","author":"Richards","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1200\/JCO.2015.63.6530","article-title":"First-in-Human Phase I\/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction","volume":"34","author":"Gertz","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1080\/13506129.2016.1205974","article-title":"2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis","volume":"23","author":"Renz","year":"2016","journal-title":"Amyloid"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1182\/blood-2018-07-865857","article-title":"Beyond NEOD001 for systemic light-chain amyloidosis","volume":"132","author":"Varga","year":"2018","journal-title":"Blood"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S0002-9440(10)64639-1","article-title":"Antibody-mediated resolution of light chain-associated amyloid deposits","volume":"157","author":"Hrncic","year":"2000","journal-title":"Am. J. Pathol."},{"key":"ref_160","first-page":"509","article-title":"Final Analysis of the Phase 1a\/b Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with Relapsed or Refractory AL Amyloidosis","volume":"130","author":"Edwards","year":"2017","journal-title":"Blood"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1182\/blood-2018-99-118464","article-title":"Improvement in Global Longitudinal Strain (GLS) Correlates with NT-Probnp Response in Patients with Cardiac Amyloidosis Treated on a Phase 1b Study of Anti-Amyloid Mab Cael-101","volume":"132","author":"Bhutani","year":"2018","journal-title":"Blood"},{"key":"ref_162","first-page":"284","article-title":"Binding of serum amyloid P-component (SAP) by amyloid fibrils","volume":"38","author":"Pepys","year":"1979","journal-title":"Clin. Exp. Immunol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"8360","DOI":"10.1073\/pnas.1817567116","article-title":"Stabilization of amyloidogenic immunoglobulin light chains by small molecules","volume":"116","author":"Morgan","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/1\/25\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:50:30Z","timestamp":1760169030000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/1\/25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,21]]},"references-count":163,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["ijms23010025"],"URL":"https:\/\/doi.org\/10.3390\/ijms23010025","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,21]]}}}